Awakn Life Sciences Completes World’s First Ketamine Treatment Study for a Range of Behavioral Addictions May 19, 2022
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of… Jan 26, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022
